J. Goldman & CO LP 89bio, Inc. Transaction History

J. Goldman & CO LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$4.83 - $10.57 $223,271 - $488,608	-46,226 Reduced 32.42%	96,339 $946,000
Q1 2025 May 15, 2025	BUY	$6.18 - $11.66 $881,051 - $1.66 Million	142,565 New	142,565 $1.04 Million
Q1 2023 May 15, 2023	SELL	$10.48 - $16.94 $456,236 - $737,465	-43,534 Reduced 80.53%	10,526 $160,000
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $298,411 - $688,183	54,060 New	54,060 $688,000

236

156M

774K

6.48M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $690M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.